基于蛋白质组学的α-烯醇酶鉴定为胆管癌潜在的预后标志物。
Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.
机构信息
Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
出版信息
Clin Biochem. 2012 Jul;45(10-11):827-34. doi: 10.1016/j.clinbiochem.2012.04.004. Epub 2012 Apr 19.
Abstract
OBJECTIVES
To investigate the association of expression status of α-enolase (ENO1) and clinicopathological outcomes of CCA patients.
DESIGN AND METHODS
Two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) were used to compare differential expressed protein profiles of four human CCA cell lines and H69, a non-malignant biliary cell line, as a control. Immunohistochemical analysis was carried out in tissue-microarray of human CCA tissues (n=301).
RESULTS
We identified ENO1 in all CCA cell lines but not H69 by proteomics based. About 75% of patients with CCA showed over-expression of ENO1 in hyperplastic bile duct and the tumors compared with that in tumor-adjacent normal tissue counterparts. Moreover, over-expression of ENO1 is significantly associated with poor prognosis and tumor invasion of CCA patients.
CONCLUSIONS
ENO1 may serve as a prognostic marker to monitor the disease progression of these patients.
摘要
目的
探讨烯醇化酶（ENO1）的表达状态与 CCA 患者临床病理结局的关系。
设计与方法
采用二维凝胶电泳（2-DE）和质谱（MS）技术比较了人 CCA 细胞系和 H69（一种非恶性胆管细胞系）作为对照的差异表达蛋白图谱。对人 CCA 组织的组织微阵列（n=301）进行免疫组织化学分析。
结果
通过基于蛋白质组学的方法，我们在所有 CCA 细胞系中均鉴定到 ENO1，但在 H69 中未鉴定到。与肿瘤旁正常组织相比，约 75%的 CCA 患者的增生性胆管和肿瘤中 ENO1 呈过度表达。此外，ENO1 的过度表达与 CCA 患者的不良预后和肿瘤侵袭显著相关。
结论
ENO1 可作为监测这些患者疾病进展的预后标志物。
相似文献
1
Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.
Clin Biochem. 2012 Jul;45(10-11):827-34. doi: 10.1016/j.clinbiochem.2012.04.004. Epub 2012 Apr 19.
2
Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.
Hum Pathol. 2012 Oct;43(10):1719-30. doi: 10.1016/j.humpath.2011.11.021. Epub 2012 Mar 24.
3
A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.
J Gastrointest Surg. 2013 Sep;17(9):1584-91. doi: 10.1007/s11605-013-2182-9. Epub 2013 Jul 19.
4
Annexin A1: A new immunohistological marker of cholangiocarcinoma.
World J Gastroenterol. 2013 Apr 28;19(16):2456-65. doi: 10.3748/wjg.v19.i16.2456.
5
Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis.
Tumour Biol. 2014 Sep;35(9):8645-52. doi: 10.1007/s13277-014-2087-6. Epub 2014 May 28.
6
Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
Oncol Rep. 2019 Dec;42(6):2622-2634. doi: 10.3892/or.2019.7387. Epub 2019 Oct 23.
7
YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Tumour Biol. 2016 Jul;37(7):9451-63. doi: 10.1007/s13277-016-4838-z. Epub 2016 Jan 19.
8
The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
PLoS One. 2015 Oct 20;10(10):e0141165. doi: 10.1371/journal.pone.0141165. eCollection 2015.
9
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients.
BMC Cancer. 2021 Jul 28;21(1):865. doi: 10.1186/s12885-021-08576-z.
10
High expression of apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3) in human cholangiocarcinoma.
Tumour Biol. 2016 Oct;37(10):13659-13667. doi: 10.1007/s13277-016-5204-x. Epub 2016 Jul 29.
引用本文的文献
1
TRPC5OS induces tumorigenesis by increasing ENO1-mediated glucose uptake in breast cancer.
Transl Oncol. 2022 Aug;22:101447. doi: 10.1016/j.tranon.2022.101447. Epub 2022 May 16.
2
Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer.
Oncol Lett. 2020 Apr;19(4):3189-3196. doi: 10.3892/ol.2020.11427. Epub 2020 Mar 3.
3
ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance.
Gastroenterol Res Pract. 2018 Feb 1;2018:3842198. doi: 10.1155/2018/3842198. eCollection 2018.
4
Biological Entanglement-Like Effect After Communication of Fish Prior to X-Ray Exposure.
Dose Response. 2018 Feb 15;16(1):1559325817750067. doi: 10.1177/1559325817750067. eCollection 2018 Jan-Mar.
5
Proteomic characterization of the internalization of Opisthorchis viverrini excretory/secretory products in human cells.
Parasitol Int. 2017 Aug;66(4):494-502. doi: 10.1016/j.parint.2016.02.001. Epub 2016 Feb 9.
6
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.
Int J Genomics. 2015;2015:179528. doi: 10.1155/2015/179528. Epub 2015 Sep 2.
7
FBXW7 negatively regulates ENO1 expression and function in colorectal cancer.
Lab Invest. 2015 Sep;95(9):995-1004. doi: 10.1038/labinvest.2015.71. Epub 2015 Jun 22.
8
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oncologist. 2015 Jul;20(7):742-51. doi: 10.1634/theoncologist.2014-0442. Epub 2015 May 29.
9
Enolase-1 is a therapeutic target in endometrial carcinoma.
Oncotarget. 2015 Jun 20;6(17):15610-27. doi: 10.18632/oncotarget.3639.
10
Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
J Hematol Oncol. 2015 Mar 8;8:22. doi: 10.1186/s13045-015-0117-5.
本文引用的文献
1
Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma.
BMC Clin Pathol. 2011 Jan 14;11:1. doi: 10.1186/1472-6890-11-1.
2
[ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients].
Zhongguo Fei Ai Za Zhi. 2010 Dec;13(12):1089-93. doi: 10.3779/j.issn.1009-3419.2010.12.02.
3
Prognostic implication of ezrin overexpression in myxofibrosarcomas.
Ann Surg Oncol. 2010 Dec;17(12):3212-9. doi: 10.1245/s10434-010-1185-y. Epub 2010 Jun 29.
4
Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker.
Int J Parasitol. 2010 Aug 15;40(10):1203-12. doi: 10.1016/j.ijpara.2010.05.002. Epub 2010 May 21.
5
ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction.
Eur J Cancer. 2010 Jun;46(9):1712-23. doi: 10.1016/j.ejca.2010.03.018.
6
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J Biomed Biotechnol. 2010;2010:437143. doi: 10.1155/2010/437143. Epub 2009 Dec 27.
7
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.
Nature. 2010 Jan 21;463(7279):364-8. doi: 10.1038/nature08697. Epub 2009 Dec 13.
8
Proteomic analysis of differentially expressed proteins in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products.
J Cell Biochem. 2009 Dec 15;108(6):1376-88. doi: 10.1002/jcb.22368.
9
A review of human carcinogens--Part B: biological agents.
Lancet Oncol. 2009 Apr;10(4):321-2. doi: 10.1016/s1470-2045(09)70096-8.
10
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma.
Int J Oncol. 2008 Oct;33(4):725-31.
Zotero 插件